An introduction to Zealand
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotechnology company with leading scientific expertise in turning peptides into medicines. Zealand has a pipeline of proprietary drug candidates which target specialty disease areas with significant unmet medical needs and a portfolio of medicines and product candidates under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.
The company’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi who markets the product globally outside the US as Lyxumia®. The fixed-ratio combination of basal insulin glargine (Lantus®) and lixisenatide, referred to as iGlarLixi, is under regulatory review in the US and Europe.
Zealand’s proprietary pipeline of drug candidates includes: ZP4207 (single-dose rescue treatment) for acute, severe hypoglycemia (Phase II); ZP1848 for Short Bowel Syndrome (Phase II); ZP4207 (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia management in diabetes (in preparation for Phase II); ZP2929 for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark.
Zealand has ~110 employees of which 80% work in research and development.
Follow us on Twitter: @ZealandPharma
Follow us on LinkedIn